Role of circulating-tumor DNA analysis in non-small cell lung cancer.

[1]  K. Nouso,et al.  Detection of K‐ras gene mutation by liquid biopsy in patients with pancreatic cancer , 2015, Cancer.

[2]  S. Stein,et al.  Circulating Cell-Free Tumour DNA in the Management of Cancer , 2015, International journal of molecular sciences.

[3]  J. Neal,et al.  Rociletinib in EGFR-mutated non-small-cell lung cancer. , 2015, The New England journal of medicine.

[4]  P. Jänne,et al.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.

[5]  Aleksandra Markovets,et al.  Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M , 2015, Nature Medicine.

[6]  K. Nouso,et al.  761 Detection of K-RAS Gene Mutation by Liquid Biopsy in Patients With Pancreatic Cancer , 2015 .

[7]  T. Mok,et al.  Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy , 2015, Clinical Cancer Research.

[8]  R. Chen,et al.  Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC , 2014, PloS one.

[9]  Yu Cao,et al.  Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing , 2014, Science.

[10]  A. Truini,et al.  Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer. , 2014, Drug discovery today.

[11]  A. Truini,et al.  Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System , 2014, Front. Oncol..

[12]  Ruey-min Lee,et al.  Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. , 2014, The Lancet. Oncology.

[13]  R. McCormack,et al.  Gefitinib Treatment in EGFR Mutated Caucasian NSCLC , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  E. Nexo,et al.  Monitoring of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Sensitizing and Resistance Mutations in the Plasma DNA of Patients With Advanced Non–Small Cell Lung Cancer During Treatment With Erlotinib , 2014, Cancer.

[15]  S. Ren,et al.  Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients , 2014, Translational oncology.

[16]  A. Bardelli,et al.  Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities. , 2014, Cancer treatment reviews.

[17]  T. Yap,et al.  Circulating Tumor Cells: A Multifunctional Biomarker , 2014, Clinical Cancer Research.

[18]  V. Velculescu,et al.  Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. , 2014, Cancer discovery.

[19]  E. Nexo,et al.  Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays , 2014, BMC Cancer.

[20]  J. Engelman,et al.  Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[21]  V. Servois,et al.  Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma , 2014, International journal of cancer.

[22]  L. Diaz,et al.  Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[24]  Antonio C. Wolff,et al.  Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer , 2014, Clinical Cancer Research.

[25]  N. Reguart,et al.  Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins. , 2014, Cancer treatment reviews.

[26]  C. Paweletz,et al.  Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA , 2014, Clinical Cancer Research.

[27]  Ash A. Alizadeh,et al.  An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage , 2013, Nature Medicine.

[28]  P. Holdgaard,et al.  The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC , 2013, British Journal of Cancer.

[29]  Quan Zhang,et al.  Comparison of EGFR signaling pathway somatic DNA mutations derived from peripheral blood and corresponding tumor tissue of patients with advanced non-small-cell lung cancer using liquidchip technology. , 2013, The Journal of molecular diagnostics : JMD.

[30]  Chun-Ming Tsai,et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Speicher,et al.  Circulating tumor cells and DNA as liquid biopsies , 2013, Genome Medicine.

[32]  Jae Cheol Lee,et al.  Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping , 2013, Journal of experimental & clinical cancer research : CR.

[33]  F. Nicolantonio,et al.  Liquid biopsy: monitoring cancer-genetics in the blood , 2013, Nature Reviews Clinical Oncology.

[34]  R. McCormack,et al.  The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies , 2013, Journal of Clinical Pathology.

[35]  Shi Yan,et al.  A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma , 2013, World Journal of Surgical Oncology.

[36]  N. Rosenfeld,et al.  Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA , 2013, Nature.

[37]  Carlos Caldas,et al.  Analysis of circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.

[38]  A. Jakobsen,et al.  The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. , 2013, Lung cancer.

[39]  M. Speicher,et al.  Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer , 2013, International journal of cancer.

[40]  Yeul-Hong Kim,et al.  Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)? , 2013, Medical Oncology.

[41]  G. Zhu,et al.  Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib , 2012, OncoTargets and therapy.

[42]  Ying-jian Chen,et al.  Direct serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis. , 2012, Oncology reports.

[43]  S. Kimura,et al.  Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[44]  Qinghua Zhou,et al.  Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Kunihiko Kobayashi,et al.  Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer. , 2012, Anticancer research.

[46]  Torunn I Yock,et al.  Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. , 2012, Cancer research.

[47]  Jun Wang,et al.  Comparison of Epidermal Growth Factor Receptor Mutation Statuses in Tissue and Plasma in Stage I–IV Non-Small Cell Lung Cancer Patients , 2012, Respiration.

[48]  J. Chung-Man Ho,et al.  EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[49]  N. Rosenfeld,et al.  Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA , 2012, Science Translational Medicine.

[50]  Charles Swanton,et al.  Intratumor Heterogeneity: Seeing the Wood for the Trees , 2012, Science Translational Medicine.

[51]  J. Whang‐Peng,et al.  Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib. , 2012, Oncology letters.

[52]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[53]  Yasushi Totoki,et al.  KIF5B-RET fusions in lung adenocarcinoma , 2012, Nature Medicine.

[54]  Yuki Togashi,et al.  RET, ROS1 and ALK fusions in lung cancer , 2012, Nature Medicine.

[55]  Koichi Goto,et al.  Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[56]  G. Hampton,et al.  Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib , 2011, Clinical Cancer Research.

[57]  Apiwat Mutirangura,et al.  Epithelial-Specific Methylation Marker: A Potential Plasma Biomarker in Advanced Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[58]  Kikuya Kato,et al.  Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas , 2011, Clinical Cancer Research.

[59]  Wei Zhang,et al.  Serum Detection of Epidermal Growth Factor Receptor Gene Mutations Using Mutant-Enriched Sequencing in Chinese Patients with Advanced Non-Small Cell Lung Cancer , 2011, The Journal of international medical research.

[60]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[61]  M. Ladanyi,et al.  Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. , 2011, Lung cancer.

[62]  Klaus Pantel,et al.  Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.

[63]  R. Rosell,et al.  The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. , 2011, Lung cancer.

[64]  Yun Zheng,et al.  Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. , 2011, Cancer letters.

[65]  E. Duhig,et al.  Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer , 2011, European Respiratory Journal.

[66]  A. Gemma,et al.  F1000 highlights , 2010 .

[67]  V. Poletti,et al.  Increased Levels of Free Circulating Dna in Patients with Idiopathic Pulmonary Fibrosis , 2010, The International journal of biological markers.

[68]  X. Wang,et al.  Potential Clinical Significance of a Plasma-Based KRAS Mutation Analysis in Patients with Advanced Non–Small Cell Lung Cancer , 2010, Clinical Cancer Research.

[69]  J. Abbruzzese,et al.  F1000 highlights , 2009, JAMA.

[70]  N. Zhong,et al.  Detection of epidermal growth factor receptor mutations in plasma by mutant‐enriched PCR assay for prediction of the response to gefitinib in patients with non‐small‐cell lung cancer , 2009, International journal of cancer.

[71]  A. Hölscher,et al.  Lack of prognostic significance of serum DNA methylation of DAPK, MGMT, and GSTPI in patients with non‐small cell lung cancer , 2009, Journal of surgical oncology.

[72]  S. Goodman,et al.  Sensitive digital quantification of DNA methylation in clinical samples , 2009, Nature Biotechnology.

[73]  L. Mao,et al.  Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  P. Jänne,et al.  Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer , 2009, Clinical Cancer Research.

[75]  T. Mok,et al.  Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non–Small Cell Lung Cancer Patients , 2009, Clinical Cancer Research.

[76]  H. C. Fan,et al.  Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood , 2008, Proceedings of the National Academy of Sciences.

[77]  R. Rosell,et al.  Retrospective analysis of the prognostic role of p16 protein inactivation in plasma in patients with locally advanced non-small cell lung cancer. , 2008, Lung cancer.

[78]  L. Crinò,et al.  Plasma DNA, Microsatellite Alterations, and p53 Tumor Mutations Are Associated with Disease-Free Survival in Radically Resected Non-small Cell Lung Cancer Patients: A Study of the Perugia Multidisciplinary Team for Thoracic Oncology , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[79]  K. Nishio,et al.  Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA) , 2007, British Journal of Cancer.

[80]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[81]  Marius Žemaitis,et al.  Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine. , 2007, Lung cancer.

[82]  S. O’Day,et al.  Utility of Circulating B-RAF DNA Mutation in Serum for Monitoring Melanoma Patients Receiving Biochemotherapy , 2007, Clinical Cancer Research.

[83]  T. Rainer,et al.  Circulating Nucleic Acids and Critical Illness , 2006, Annals of the New York Academy of Sciences.

[84]  K. Nishio,et al.  EGFR Mutation of Tumor and Serum in Gefitinib-Treated Patients with Chemotherapy-Naive Non–small Cell Lung Cancer , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[85]  M. Kris,et al.  Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma , 2005, Cancer.

[86]  Frank Diehl,et al.  Detection and quantification of mutations in the plasma of patients with colorectal tumors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[87]  Keitaro Matsuo,et al.  Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[88]  Wen-Shyong Tzou,et al.  Molecular Detection of APC, K-ras, and p53 Mutations in the Serum of Colorectal Cancer Patients as Circulating Biomarkers , 2004, World Journal of Surgery.

[89]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[90]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[91]  K. Jung,et al.  Changes in concentration of DNA in serum and plasma during storage of blood samples. , 2003, Clinical chemistry.

[92]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[93]  F. O. Fackelmayer,et al.  DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. , 2001, Cancer research.

[94]  V. Vasioukhin,et al.  The Origin and Mechanism of Circulating DNA , 2000, Annals of the New York Academy of Sciences.

[95]  T. Walsh,et al.  Microsatellite alterations plasma DNA of primary breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[96]  M. Barbacid,et al.  Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. , 1984, Science.

[97]  B. Shapiro,et al.  Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.

[98]  T. Wilczok,et al.  Circulating DNA as a Possible Factor in Oncogenesis , 1965, Science.

[99]  P Mandel,et al.  Les acides nucleiques du plasma sanguin chez l' homme , 1948 .

[100]  Peter Ulz,et al.  Circulating tumor DNA as a liquid biopsy for cancer. , 2015, Clinical chemistry.

[101]  K. Pantel,et al.  Biologic challenges in the detection of circulating tumor cells. , 2013, Cancer research.

[102]  K. Tsao,et al.  Elevated cell-free serum DNA detected in patients with myocardial infarction. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[103]  D. Jb,et al.  Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases. , 2002 .

[104]  M. Stroun,et al.  Neoplastic characteristics of the DNA found in the plasma of cancer patients. , 1989, Oncology.